NEO - מחיר לרווח מתואם קצב צמיחה NeoGenomics, Inc.

NeoGenomics, Inc. (NEO) generates revenue from genetic tumor analysis and biomarkers, leveraging patent protection and close ties with medical centers. The level of undervaluation based on the PEG ratio demonstrates valuation resilience to shocks, while the value of 1.14 characterizes this level. Business growth is driven by new contracts with pharmaceutical companies, the implementation of RaDaR liquid biopsy, and the optimization of internal costs.

NeoGenomics, Inc. (NEO) is building critical oncology diagnostic infrastructure by integrating laboratory testing and pharmaceutical research to advance targeted therapy. The PEG ratio allows for the valuation of each unit of future EPS growth, where a PEG ratio below one signals that the asset is undervalued relative to its expansion, helping investors identify undervalued growth leaders.